Bio Path reported $259K in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Alterity Therapeutics Limited AUD 1.45M 703.96K Dec/2025
Baxter International USD 735M 7M Jun/2026
Bio Path USD 259K 60K Mar/2026
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.43M 222K Mar/2026
CSL USD 1.23B 498M Dec/2025
Grifols EUR 320.45M 12.65M Dec/2025
Karyopharm Therapeutics USD 10.42M 861K Mar/2026